

OBIS STRATEGIC INVESTMENT SERIES – 2027

From Scientific Innovation to Investment Structure and Institutional Growth.

WHAT THE SERIES IS

OBIS Strategic Investment Series – 2027 is an integrated investor framework created to present the financial, scientific, intellectual-property and strategic architecture of OBIS Innovation & Solutions Inc. in a coherent and decision-oriented format.

The Series brings together 10 interconnected documents designed to explain how value is created, protected, financed and progressively de-risked across the OBIS biotechnology platform.

Rather than presenting isolated financial projections, the Series connects market opportunity, portfolio architecture, capital formation, intellectual property, development milestones, valuation and strategic collaboration within one unified investment narrative.



THE 2027 INVESTMENT ARCHITECTURE

LPS™: Flagship commercial and health-economic reference case, modeled through clearly defined U.S. market scenarios.

SPI™: Conditional high-impact program evaluated through scientific, market and long-horizon value-creation scenarios.

OBIS Platform Portfolio: A current external biotechnology portfolio framing of 72 proposed products across six generations. Structured for staged prioritization, protection, validation and partnering.

Capital & Value Creation: A financing architecture linking seed capital to defined milestones, risk reduction and future institutional investment readiness



THE INVESTMENT OPPORTUNITY

OBIS enters the 2027 investment cycle with a defined US\$1.2 million seed financing objective designed to strengthen the foundations required for scientific execution, intellectual-property protection, regulatory preparation and institutional capital readiness.

This is not financing for a single isolated product.

It is participation in an emerging biotechnology platform whose value is supported by flagship programs, a broader candidate portfolio, proprietary scientific architecture and multiple potential routes to licensing, co-development and strategic collaboration.

IMMEDIATE CAPITAL PRIORITIES

- Early R&D and proof-of-concept execution.
- Intellectual-property protection and priority filings.
- Regulatory, quality and CMC preparation.
- Corporate, legal, tax and financial readiness.
- Minimum operating and scientific coordination capability.
- Controlled investor materials and due-diligence infrastructure.
- Preparation for subsequent institutional financing.

VALUE PROPOSITION FOR INVESTORS

The seed round is designed to convert existing scientific and strategic architecture into stronger evidence, stronger protection and stronger execution capability.

Its purpose is not immediate large-scale commercialization. Its purpose is to reduce specific uncertainties and establish the foundation from which future institutional capital can accelerate development.

2027 INVESTMENT SNAPSHOT

US\$1.2M Seed financing objective	US\$5.448B Current formula-driven Pre-Money Valuation.	72 proposed products across six generations.
LPS™ Flagship quantified commercial reference	SPI™ Conditional high-impact strategic program	2027–2034 Platform development and value-creation horizon



WHY THE SERIES MATTERS

Early-stage biotechnology companies are often evaluated through individual assets, isolated market estimates or conventional financial projections.

OBIS follows a broader platform approach.

The Strategic Investment Series connects each investment decision to the scientific, commercial, legal and institutional elements that determine whether potential value can become executable value.

DIFFERENTIATED VALUE PROPOSITION

Flagship-to-Platform Strategy: LPSTTM and SPITTM provide focused reference programs while the broader biotechnology portfolio creates diversification and future program-generation capacity.

Milestone-Linked Value Creation: Value is expected to evolve as intellectual property, reproducible evidence, regulatory clarity, manufacturability, external validation and strategic transactions reduce uncertainty.

Protected Intellectual Property Perimeter: Background IP, proprietary know-how and enabling technical information remain controlled while sufficient information is provided for qualified investment review.

Capital Discipline: Each major use of capital is associated with identifiable capabilities, evidence packages, milestones or reductions in risk.

Strategic Optionality: Licensing, co-development, sponsored research, strategic investment and institutional partnerships may provide multiple routes to value realization.

THE PLATFORM PRINCIPLE

The 72-product platform across six generations is not valued through a mechanical multiplication of individual assets.

Its significance lies in the ability of the platform to generate, prioritize and progressively develop multiple opportunities over time.

Flagship programs + portfolio optionality + intellectual property + scientific architecture + strategic execution

A CONTROLLED APPROACH TO VALUE

The current formula-driven Pre-Money Valuation is US\$5.448B under the 2027 standard. This model-derived investment reference will be recalibrated when material scientific, financial, IP or portfolio assumptions change.

This discipline is intentional.





STRATEGIC VISION 2027–2034

1. Definition, Protection & Foundational

Execution: Strengthen corporate readiness, establish priority intellectual-property protection, advance early proof-of-concept programs, reinforce regulatory and quality planning, and organize the platform for professional due diligence and institutional collaboration.

2. Validation, Development & Strategic

Partnerships: Generate reproducible scientific evidence, expand prioritized development programs, establish sponsored research and co-development structures, progress regulatory pathways and engage qualified investors, research institutions and commercial partners.

3. Scale, Transactions & Portfolio

Expansion: Advance selected programs toward licensing, commercialization or strategic transactions; expand the protected portfolio; strengthen manufacturing and delivery capabilities; and position OBIS for broader international participation.

INTELLECTUAL PROPERTY

The first priority provisional filing workstreams currently include:

LPS™ • PAK™ • CMPT™ • SPI™

The broader 72-product platform across six generations represents additional future scientific, IP and transaction optionality.

The term Patent Pending is applied only after the corresponding application has actually been filed.

STRATEGIC COLLABORATION

OBIS distinguishes among:

Scientific collaboration • Sponsored research • Strategic investment • Licensing & co-development • Business development

Participation in one channel does not automatically create rights in another.

Background IP, equity, research funding, commercial rights, milestones and royalties are treated through their appropriate contractual instruments.

CONFIDENTIALITY

Detailed formulations, enabling technical information, proprietary architectures, claim strategies and other replicable intellectual property are not disclosed through the general investor series.

Expanded technical and documentary information may be provided to qualified parties under appropriate confidentiality and due-diligence procedures.

FINAL STATEMENT

OBIS Strategic Investment Series – 2027 is a structured framework connecting science, capital, intellectual property, milestones and collaboration within a unified investment logic. It defines OBIS's current position, next priorities and pathways for value creation.